Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'FDA'  -  Page 6
Latest

Net losses grow at Sientra during third quarter

By   /  Tuesday, November 7th, 2017  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Net losses grow at Sientra during third quarter

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Westlake Village biotech company MannKind restructures debt

By   /  Monday, October 23rd, 2017  /  Central Coast Health Watch, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Westlake Village biotech company MannKind restructures debt

MannKind announced Oct. 23 that it had restructured debt due in 2018, exchanging $27.7 million in convertible notes for $23.7 million due in October of 2021 and nearly 1 million shares of its common stock. The new convertible senior subordinated exchange notes have a rate of 5.75 percent, the Westlake Village-based biotech company said in Read More →

Read More →
Latest

Amgen settles with AbbVie over Humira biosimilar

By   /  Thursday, September 28th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen settles with AbbVie over Humira biosimilar

Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →

Read More →
Latest

FDA approves Amgen cancer treatment biosimilar Mvasi

By   /  Thursday, September 14th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA approves Amgen cancer treatment biosimilar Mvasi

The U.S. Food and Drug Administration approved a cancer treatment biosimilar developed in partnership between Allergan and Thousand Oaks-based Amgen, the company announced Sept. 13. Mvasi was approved to treat five types of cancer in combination with other therapies. “The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first Read More →

Read More →
Latest

Amgen stock drops despite strong earnings

By   /  Friday, July 28th, 2017  /  Central Coast Health Watch, Earnings, East Ventura County, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen stock drops despite strong earnings

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Goleta medical device maker stocks are hot

By   /  Friday, July 21st, 2017  /  Central Coast Health Watch, Earnings, Latest news, South Coast, Technology, Tri-County Public Companies  /  Comments Off on Goleta medical device maker stocks are hot

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen partnering to develop new drugs

By   /  Friday, July 21st, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen partnering to develop new drugs

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →